News | February 6, 2008

Contract Services For Big Pharma And Biotechs Driving Growth And Innovation From Discovery To Clinical Trials

Over the past few years, the strategic importance of the global pharmaceutical marketplace has become increasingly apparent. Multinational interest and investment in the global pharmaceutical industry is at an all-time high and competition is heating up. On one hand big pharma is pumping in more resources into outsourcing and offshoring. On the other hand, drug safety issues, threat from biogenerics, stricter protocols for APIs and pharmacovigilance issues question some existing models and frameworks. More than ever, as the demand intensifies to fill the pharmaceutical pipeline with new drugs and therapeutics -- outsourcing partnerships are playing an increasingly critical role.

The 2008 BioPharma Outsourcing: Partnerships with CROs and Other Service Providers forum, scheduled for March 25-26, 2008 at the Hilton Boston Back Bay in Boston, MA is designed to bring together pharma and biotech executives from around the world to gather strategic information and creating networking relationships all eager to facilitate new investments and partnerships.

Distinguished Speaker Roster Includes (updated as of February 6, 2008):

  • Diana M. Galer Ph.D., VP, Strategic Management Group, Pfizer Global Research & Development
  • Mark Tracy, Senior Director, Pharmaceutical Operations, Alnylam Pharmaceuticals
  • RoseAnn Price, Alliance Management, Amgen
  • Mel Sorensen, M.D., President & CEO, Ascenta Therapeutics, Inc.
  • Ahsan Awan, JD, MBA, CRCP, Global CINRG, Inc.
  • Gur Roshwalb, MD, VP & Senior Analyst Health Care, Piper Jaffray & Co.
  • Han Gunn, Preclinical Director, Department of Pharmacokinetics & Drug Metabolism, Amgen
  • Partha S. Ray, MD, CEO, IndusPharma Consulting Group
  • Michael Palladino, PhD, Senior VP, CTO, & Scientific Co-Founder, Nereus Pharmaceuticals
  • Steve J. Bannister, PhD, Chief Scientific Officer, Xcelience, LLC
  • Judd Berman, PhD., Chief Scientific Officer, Dalton Medicinal Chemistry
  • Zhengming (Jimmy) Chen, PhD, Senior Director, Chemistry and CMC, DOV Pharmaceutical, Inc.
  • John Lemelan, General Partner, Riverside Partners
  • Dean Wilson, PhD, Research Fellow, Vertex Pharmaceuticals
  • John Maclennan, PhD, Director, Business Development, Wolfe Laboratories, Inc.

For Complete List of Speakers, Detailed Agenda, and to Register: www.iibig.com/P0803

SOURCE: iiBIG